GLP-1 Pipeline Update: February 2026 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Associate Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Drug Information Pharmacist Principal Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Development Director Senior, Pipeline DISCLAIMER The drug pipeline is fluid
GLP-1 Market: Distribution by Type (Long,Short Acting) of GLP-1 Agonist Drugs, 2020, 2024 and 2035 14.3
External and iatrogenic causes: Excessive supplementation: High-dose oral supplements or frequent intramuscular injections (hydroxocobalamin or cyanocobalamin) can elevate serum levels, though this rarely causes problems
For an obesity market that Truist describes as highly elastic, the strategy is straightforward and hinges on lowering cost, improving access, and increasing duration on therapy
When metabolism slows, the body tends to use fewer calories, and fat reduction becomes more challenging
The study evaluated patients after nine weeks of treatment with cisplatin alone or with cisplatin and glutathione